IMCIVREE 10 mg/ml sol inj 10 mg 1 pce

7680696940014 CH-69694 A08AA12 01.11.0.
IMCIVREE 10 mg/ml sol inj 10 mg 1 pce
IMCIVREE 10 mg/ml sol inj 10 mg 1 pce
IMCIVREE 10 mg/ml sol inj 10 mg 1 pce
1 / 3
google

Details

GTIN
7680696940014
Pharmacode
-
Product number
6969401
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
setmelanotidum 10 mg, N-(carbonyl-methoxypolyethylenglycoli 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolaminum natricum, alcohol benzylicus 10 mg, carmellosum natricum, mannitolum, phenolum, dinatrii edetas, natrii hydroxidum aut acidum hydrochloridum ad pH, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 1.64 mg.

Articles (1)

IMCIVREE 10 mg/ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
09/06/2026
Professional SmPC
Français
09/06/2026
Professional SmPC
Italien
09/06/2026
Patient information leaflet
Allemand
23/05/2026
Patient information leaflet
Français
23/05/2026
Patient information leaflet
Italien
23/05/2026

Detailed composition

Substance Quantity Type Category
setmelanotidum
10.0 MG Substance Wirkstoff (Principe actif)
N-(carbonyl-methoxypolyethylenglycoli 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolaminum natricum
- Substance HNIDK
alcohol benzylicus
10.0 MG Substance HBESI
carmellosum natricum
- Substance HNIDK
mannitolum
- Substance HNIDK
phenolum
- Substance Konservierungsstoff (Conservateur)
dinatrii edetas
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
acidum hydrochloridum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.64 MG Substance HBESI

Authorization holder

Rhythm Pharmaceuticals Switzerland GmbH

6300 Zug

Authorization information

Swissmedic authorization number
69694
Drug name
IMCIVREE, Injektionslösung
Galenic form
LSINJ
ATC Code
A08AA12
Authorization status
Z
Dispensation category
B
First authorization
23/06/2025
Authorization expiration date
22/06/2030
IT number
01.11.0.
Domain
Human medicine
Field of application
bei Erwachsenen und Kindern ab 2 Jahren zur Behandlung von Adipositas und zur Kontrolle des Hungergefühls im Zusammenhang mit genetisch bestätigtem Bardet-Biedl-Syndrom (BBS), durch Funktionsverlustmutationen bedingtem biallelischem Proopiomelanocortin (POMC)-Mangel (einschliesslich PCSK1) oder biallelischem Leptinrezeptor (LEPR)-Mangel

Packaging details

Description (FR)
IMCIVREE 10 mg/ml sol inj 10 mg 1 pce
Description (DE)
IMCIVREE 10 mg/ml Inj Lös 10 mg 1 Stk
Market launch
03/12/2025
Narcotic (BTM)
No
Buy us a coffee Explore the data